The GLP-1 Patient's Guide to Facial Volume Loss: Why Sculptra Works Where Fillers Fall Short
- 5 hours ago
- 5 min read
This is the clinical reality of what has come to be called Ozempic face. And it deserves a clinical answer, not a social media one.
· · ·
What is Ozempic Face and Why Does It Happen
Ozempic face refers to facial volume depletion and soft tissue laxity following rapid weight loss associated with GLP-1 medication. As total body fat decreases, facial fat decreases with it. The face does not protect its fat reserves any more than the abdomen or the thighs do.[1]
Clinical trials have shown semaglutide use can lead to weight reductions of 14.9% to 17.4% in individuals without diabetes.[3] As body fat decreases, facial fat is often lost dramatically. The result is hollowing of the temples, flatness of the mid-face, deepening of the nasolabial folds, loss of jawline definition, and a general gauntness that can add years to the appearance in a matter of months.
This is one of the most common presentations Dr. Aguilar sees from GLP-1 patients. You have done everything right. You have achieved significant, health-improving weight loss. And your face is reflecting it in a way that feels like it has aged rather than improved. The good news is that this is a treatable condition with well-established, non-surgical options.[2]
Why GLP-1 Facial Volume Loss is Different From Normal Ageing
In normal ageing, facial volume loss is incremental. Fat pads diminish slowly over years and decades. The skin has time to partially adapt. In GLP-1 patients, the fat loss is rapid and the skin has not had time to contract. The structural fat that supported the overlying skin is gone, but the skin itself remains, now with inadequate support beneath it.[1]
The result is a combination of deflation and laxity that can be more pronounced than would be expected for the patient's age, and that can appear suddenly rather than gradually. This is why the clinical approach for GLP-1 patients differs from a standard anti-ageing treatment plan, and why the volume of treatment required can be greater than expected.
Why Fillers Alone Often Fall Short for GLP-1 Patients
The pattern of volume loss in GLP-1 patients is typically broad and global. Addressing this with hyaluronic acid filler alone requires very large volumes to create meaningful change across the full extent of the loss. Large volumes of HA filler in a face that has lost its fat pad infrastructure can create an overfilled, unnatural appearance, the cheeks look full but the face does not look like the patient's own face.[4]
Your concern is clinically well-founded. For patients with the degree and pattern of volume loss that typically follows significant GLP-1 weight loss, large volumes of hyaluronic acid filler in the cheeks can create an appearance that looks treated rather than restored. Sculptra is considered the gold standard for treating significant facial volume loss from GLP-1 medications, stimulating your own collagen production and rebuilding facial structure from within.[4]
Why Sculptra is the Preferred Treatment for GLP-1 Facial Volume Loss
Sculptra was originally developed and approved precisely for patients who had lost facial fat rapidly, HIV patients experiencing lipoatrophy from their medications. The mechanism of loss is different but the pattern of facial change is strikingly similar: rapid, significant fat pad depletion leaving deflated, lax skin over a broad area of the face. Sculptra was built for this problem.[5]
The Combination Approach: Sculptra and HA Filler Together
In many post-GLP-1 patients, the most effective treatment plan involves both Sculptra and hyaluronic acid filler, used strategically and in the right sequence. A groundbreaking Galderma clinical trial demonstrated that 91.4% of patients would recommend a combination of Sculptra and Restylane injections to others experiencing medication-driven facial volume loss.[4]
Sculptra addresses the global structural loss, the broad flattening of the mid-face, the temple hollowing, the general deflation. Hyaluronic acid filler addresses specific, targeted concerns that benefit from immediate precise placement, tear trough hollowing, a deep specific fold, lip definition. Dr. Aguilar's clinical approach is typically to begin with Sculptra to establish the structural foundation, and to introduce targeted HA filler once the collagen response is underway.
Sculptra is well suited to the pattern of change these patients experience and the evidence supports its use. Three sessions is a reasonable starting expectation for most post-GLP-1 patients with moderate volume loss. Those with more significant depletion may require more. The number of sessions depends heavily on the degree of fat loss, the patient's age, and their skin quality.[4]
When Should You Start Treatment, During or After Weight Loss
The question of when to begin treatment lacks clear clinical consensus. Some practitioners advocate for preventive treatments during weight loss to maintain facial volume, while others recommend waiting until weight has stabilised for three to six months to avoid overcorrection.[2]
Dr. Aguilar's clinical preference for most patients is to begin Sculptra treatment once weight loss has plateaued or is clearly slowing, but not necessarily to wait until GLP-1 medication has been stopped. Treatment should be individually planned based on the patient's specific GLP-1 timeline, degree and rate of weight loss, age, and baseline skin quality.
What to Expect From Sculptra After GLP-1 Weight Loss
The initial sessions will not produce visible change. This is the nature of Sculptra's mechanism and it is especially important for GLP-1 patients to understand, because they are often arriving already distressed about their appearance and hoping for immediate improvement. The improvement will come, but it requires patience. Most patients begin to notice meaningful change at six to eight weeks after the second session.[6]
The aftercare protocol, the rule of fives, is critical. Massaging the treated area for five minutes, five times a day, for five days after each session helps the PLLA microparticles distribute evenly and reduces the risk of nodule formation. Post-GLP-1 patients whose skin has lost some of its structural support may be at slightly higher risk of uneven distribution if the massage protocol is not followed.
Sculptra for Ozempic Face in Nottingham, Birmingham and Leeds
Dr. Gabriela Aguilar offers Sculptra treatment for GLP-1 related facial volume loss at all three of her clinic locations. She has specific experience treating the pattern of facial change seen in GLP-1 patients and will carry out a detailed facial assessment at consultation, taking into account the patient's weight loss timeline, the degree and distribution of volume loss, their skin quality, and their aesthetic goals.
If you are using or have recently used semaglutide, tirzepatide or another GLP-1 medication and have noticed changes to your facial appearance, a consultation with Dr. Aguilar is the appropriate first step.
Consultations can be booked via here or by contacting the clinic directly.
References
PubMed / Journal of Plastic, Reconstructive and Aesthetic Surgery (2024). The rise of Ozempic face: trends and treatment challenges.pubmed.ncbi.nlm.nih.gov/39098289
MDPI Cosmetics (2025). Semaglutide-induced facial changes: recognition, counselling and treatment options.mdpi.com/journal/cosmetics
Wilding et al. (2023). Semaglutide weight reduction outcomes: 14.9% to 17.4% weight loss in non-diabetic patients.
Galderma clinical trial (2024). 91.4% of patients recommended combination Sculptra and HA filler for medication-driven facial volume loss.galderma.com/sculptra
Carey et al., HIV Medicine (2009). Durable correction of HIV lipoatrophy with poly-L-lactic acid at 48 weeks.pubmed.ncbi.nlm.nih.gov/19245538
Cleveland Clinic (2025). Sculptra: what it is, how it works, and what to expect.my.clevelandclinic.org
Comments